TAMARA J. ERICKSON APPOINTED TO ALLERGAN BOARD
TAMARA J. ERICKSON APPOINTED TO ALLERGAN BOARD IRVINE, Calif., June 23 /PRNewswire/ -- Allergan, Inc.
(NYSE: AGN) Chairman Gavin S. Herbert announced today that Tamara J. Erickson, vice president and a managing director of Arthur D. Little, Inc., has been appointed to its board of directors. "We are pleased to have Tamara join our board," said Herbert. "Her expertise in pharmaceutical research and product development management will help translate Allergan's corporate strategy into operational practices." Erickson's appointment, effective immediately, increases the number of Allergan directors to 12.
"I'm enthusiastic about working with the Allergan management team, and honored to sit on the board," Erickson said. "I'm impressed with the company's development to date and intrigued with the array of options now available for competing in the global health care market. I look forward to adding my perspective to management's discussions of how best to shape the company's growth." "Tamara will well represent our shareholders and will be of value to management in several areas," said William C. Shepherd, president and chief executive officer. "She has been active in quality programs, research and development management, and health care; and brings this knowledge and experience to the board and the management team." Erickson is the managing director of Arthur D. Little's Management Consulting business in North America. As a consultant, she has extensive experience working with health care companies around the world on issues of strategy and organization, with particular emphasis on the management of technology. She is co- author of the book "Third Generation R&D: Managing the Link to Corporate Strategy" published by Harvard Business School Press in 1991. Erickson received her master's degree in Business Administration at Harvard Graduate School of Business Administration. She is a member of the Industrial Research Institute and the Commercial Development Association. Allergan, Inc., headquartered in Irvine, is a global provider of specialty therapeutic products; is expanding beyond skin care and its leadership position in eye care into adjacent markets; and is pursuing other core technologies. -0- 6/23/92 /CONTACT: Shel Holtz (Media), 714-752-4387 (work) or 818-366-5296 (home); or Jeff D'Eliscu (Investor Relations), 714-752-4636 (work) or 714-675-9475 (home), both of Allergan/ (AGN) CO: Allergan, Inc. ST: California IN: MTC SU: PER
CH -- LA018 -- 2985 06/23/92 16:28 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 23, 1992|
|Previous Article:||CARRIAGE'S CHAIRMAN ANNOUNCES SERIOUS ILLNESS|
|Next Article:||TITAN AWARDED TENNESSEE VALLEY AUTHORITY CONTRACT|
|ALLERGAN ANNOUNCES RETIREMENT OF DAVE BRUNS|
|(Repeating to fix garble at end of text)|
|ERICKSON NAMED CEO OF TELIOS PHARMACEUTICALS|
|ALLERGAN LIGAND RETINOID THERAPEUTICS APPOINTS TWO DIRECTORS|
|Anido and Simon Join Deltagen Board.|